ClinicalTrials.gg
CompletedNCT00635713Updated Apr 10, 2009

Second Line Breast Cancer Trial

A Phase 3 interventional study of Fulvestrant and Anastrozole in Advanced Breast Cancer, sponsored by AstraZeneca. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-04-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
588
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Planned enrollment
12th of 94
588 · median 71
Started
1997
the only one that year
Phase 3
21 of 95
3 open now
Registered
31st of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 12th largest by planned enrollment of the 94 interventional ones that give a count, is the only one that started in 1997, is one of 21 in phase 3, and was the 31st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • Advanced breast cancer, FASLODEX, ARIMIDEX, Fulvestrant, Anastrozole, postmenopausal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with confirmation of breast cancer
  • objective evidence of recurrence or progression of breast cancer no more than 1 prior hormonal therapy for breast cancer

Exclusion criteria

Exclusion Criteria:

  • presence of life-threatening visceral disease
  • previous treatment with FASLODEX, ARIMIDEX or any aromatase inhibitor for breast cancer
  • more than 1 prior endocrine medical treatment for advanced breast cancer .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
588 participants (estimated)

Study arms

  • Experimental
    1

    Faslodex 125mg and Arimidex 1 mg

    Drug: Fulvestrant · Drug: Anastrozole

  • Experimental
    2

    Faslodex 250mg and Arimidex 1mg

    Drug: Anastrozole · Drug: Fulvestrant

Interventions

06

What researchers measure

Primary outcomes

  1. time to tumor progression

    Time frame: Every 3 months

Secondary outcomes

  1. objective tumor response

    Time frame: Every 3 months

  2. time to treatment failure

    Time frame: Every 3 months

  3. time to death

    Time frame: Every 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 1997 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2008
First posted
Mar 14, 2008
Start
May 1997
CompletionActual
Sep 2004
Last update
Apr 10, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00635713
Lead sponsor
AstraZeneca
First posted
Mar 14, 2008
Start date
May 1997
Completion
Sep 2004
Last update
Apr 10, 2009

Study contacts

Guido Hoctin-Boes
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion